Bayer is making clear its ambitions in cell and gene therapy with a $4 billion acquisition of US biotech Asklepios BioPharmaceutical, also known as AskBio.
Cell and gene therapies could prove disruptive in terms of the life-changing benefits they could bring to people with rare diseases and cancers – but they could also mean healthcare systems
Patients with the rare blood disorders transfusion-dependent β-thalassemia (TDT) have shown spectacular results in clinical trials of bluebird bio's gene therapy, raising hopes the treatmen
Two pioneers in the parallel technologies of cell therapy and gene therapy have come together in an ambitious alliance to develop new cancer therapies.